Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

An open-label trial of escitalopram in pervasive developmental disorders.

Owley T, Walton L, Salt J, Guter SJ Jr, Winnega M, Leventhal BL, Cook EH Jr.

J Am Acad Child Adolesc Psychiatry. 2005 Apr;44(4):343-8.

PMID:
15782081
2.

Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.

Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, Dunbar F.

Pediatrics. 2004 Nov;114(5):e634-41. Epub 2004 Oct 18.

PMID:
15492353
3.

Open-label trial of escitalopram in the treatment of posttraumatic stress disorder.

Robert S, Hamner MB, Ulmer HG, Lorberbaum JP, Durkalski VL.

J Clin Psychiatry. 2006 Oct;67(10):1522-6.

PMID:
17107242
4.

[Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].

Azorin JM, Llorca PM, Despiegel N, Verpillat P.

Encephale. 2004 Mar-Apr;30(2):158-66. French.

PMID:
15107719
5.

Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.

Research Units on Pediatric Psychopharmacology Autism Network.

Arch Gen Psychiatry. 2005 Nov;62(11):1266-74.

PMID:
16275814
6.

Open-label study of olanzapine in children with pervasive developmental disorder.

Kemner C, Willemsen-Swinkels SH, de Jonge M, Tuynman-Qua H, van Engeland H.

J Clin Psychopharmacol. 2002 Oct;22(5):455-60.

PMID:
12352267
7.

Escitalopram in the treatment of impulsive-compulsive internet usage disorder: an open-label trial followed by a double-blind discontinuation phase.

Dell'Osso B, Hadley S, Allen A, Baker B, Chaplin WF, Hollander E.

J Clin Psychiatry. 2008 Mar;69(3):452-6.

PMID:
18312057
8.

Use of citalopram in pervasive developmental disorders.

Namerow L, Thomas P, Bostic JQ, Prince J, Monuteaux MC.

J Dev Behav Pediatr. 2003 Apr;24(2):104-8.

PMID:
12692455
9.

Comparison of long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder. An open label maintenance study.

Gencer O, Emiroglu FN, Miral S, Baykara B, Baykara A, Dirik E.

Eur Child Adolesc Psychiatry. 2008 Jun;17(4):217-25.

PMID:
18026891
10.

A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone.

Masi G, Cosenza A, Mucci M, Brovedani P.

J Clin Psychiatry. 2003 Sep;64(9):1039-47.

PMID:
14628979
11.

Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients.

Burke WJ, Gergel I, Bose A.

J Clin Psychiatry. 2002 Apr;63(4):331-6.

PMID:
12000207
12.

Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study.

Davidson JR, Bose A, Korotzer A, Zheng H.

Depress Anxiety. 2004;19(4):234-40.

PMID:
15274172
14.

Escitalopram for comorbid depression and anxiety in elderly patients: A 12-week, open-label, flexible-dose, pilot trial.

Mohamed S, Osatuke K, Aslam M, Kasckow J.

Am J Geriatr Pharmacother. 2006 Sep;4(3):201-9.

PMID:
17062320
15.

A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders.

McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, Price LH.

Arch Gen Psychiatry. 1998 Jul;55(7):633-41.

PMID:
9672054
16.

[Efficacy and tolerability of escitalopram in anxiety disorders: a review].

Pelissolo A.

Encephale. 2008 Sep;34(4):400-8. doi: 10.1016/j.encep.2008.04.004. Epub 2008 Aug 15. Review. French.

PMID:
18922243
17.

Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation.

McDougle CJ, Brodkin ES, Naylor ST, Carlson DC, Cohen DJ, Price LH.

J Clin Psychopharmacol. 1998 Feb;18(1):62-6.

PMID:
9472844
18.
19.

Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care.

Wade A, Michael Lemming O, Bang Hedegaard K.

Int Clin Psychopharmacol. 2002 May;17(3):95-102.

PMID:
11981349
20.

Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study.

Potenza MN, Holmes JP, Kanes SJ, McDougle CJ.

J Clin Psychopharmacol. 1999 Feb;19(1):37-44.

PMID:
9934941
Items per page

Supplemental Content

Write to the Help Desk